The DDX41 gene, encoding a DEAD-box type ATP-dependent RNA helicase, is rarely but reproducibly mutated in myeloid diseases. The acquired mutation in DDX41 is highly concentrated at c.G1574A (p.R525H) in the conserved motif VI located at the C-terminus of the helicase core domain where ATP interacts and is hydrolyzed. Therefore, it is likely that the p.R525H mutation perturbs ATPase activity in a dominant-negative manner. In this study, we screened for the DDX41 mutation of CD34-positive tumor cells based on mRNA sequencing and identified the p.R525H mutation in three cases among 23 patients. Intriguingly, these patients commonly exhibited acute myeloid leukemia (AML) with peripheral blood cytopenias and low blast counts, suggesting that the mutation inhibits the growth and differentiation of hematopoietic cells. Data from cord blood cells and leukemia cell lines suggest a role for DDX41 in preribosomal RNA processing, in which the expression of the p.R525H mutant causes a certain ribosomopathy phenotype in hematopoietic cells by suppressing MDM2-mediated RB degradation, thus triggering the inhibition of E2F activity. This study uncovered a pathogenic role of p.R525H DDX41 in the slow growth rate of tumor cells. Age-dependent epigenetic alterations or other somatic changes might collaborate with the mutation to cause AML.
The DDX41 gene, encoding a DEAD-box type ATP-dependent RNA helicase, is rarely but reproducibly mutated in myeloid diseases. The acquired mutation in DDX41 is highly concentrated at c.G1574A (p.R525H) in the conserved motif VI located at the C-terminus of the helicase core domain where ATP interacts and is hydrolyzed. Therefore, it is likely that the p.R525H mutation perturbs ATPase activity in a dominant-negative manner. In this study, we screened for the DDX41 mutation of CD34-positive tumor cells based on mRNA sequencing and identified the p.R525H mutation in three cases among 23 patients. Intriguingly, these patients commonly exhibited acute myeloid leukemia (AML) with peripheral blood cytopenias and low blast counts, suggesting that the mutation inhibits the growth and differentiation of hematopoietic cells. Data from cord blood cells and leukemia cell lines suggest a role for DDX41 in preribosomal RNA processing, in which the expression of the p.R525H mutant causes a certain ribosomopathy phenotype in hematopoietic cells by suppressing MDM2-mediated RB degradation, thus triggering the inhibition of E2F activity. This study uncovered a pathogenic role of p.R525H DDX41 in the slow growth rate of tumor cells. Age-dependent epigenetic alterations or other somatic changes might collaborate with the mutation to cause AML. Copyright Ó 2016 ISEH -International Society for Experimental Hematology. Published by Elsevier Inc.
Current comprehensive sequencing approaches led to the identification of rare but reproducible somatic gene mutations in myeloid malignancies. Among them, there is a somatic mutation in the DDX41 gene encoding a DEAD-box type ATP-dependent RNA helicase. The somatic mutation in DDX41 is highly concentrated at c.G1574A (p.R525H) in the conserved motif VI, located at the C-terminus of the RecA-like helicase core domain where ATP interacts and is hydrolyzed. Therefore, it is likely that the p.R525H mutation in the DDX41 protein perturbs ATPase activity in a dominant-negative manner. In addition, germline mutations in DDX41 were recently isolated in a subset of familial acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) pedigrees [1, 2] . Because the roles of these somatic and germline mutations in the pathogenesis of myeloid diseases are not completely understood, the researchers who first described these mutations advocate a role for DDX41 in mRNA splicing via Offprint requests to: Hirotaka Matsui, Department of Molecular Laboratory Medicine, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, Japan 860-8556; E-mail: hmatsui@kumamoto-u.ac.jp or Tatsuo Ichinohe, MD, PhD, Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, Japan 784-8553; E-mail: nohe@hiroshima-u.ac.jp interaction with the U2 and U5 complexes [1] . However, unlike canonical spliceosomal mutations, the DDX41 mutation causes, not only MDS, but also primary AML.
In this study, we propose a role for DDX41 as a precursor ribosome RNA (pre-rRNA) processing factor in which the p.R525H mutation affects ribosome biogenesis. We found that ribosome biogenesis was affected widely when cord blood-derived CD34-positive cells were transfected with DDX41 p.R525H, thus compromising cell cycle progression through impaired E2F function. Because molecular mechanisms for the development of AML with cytopenias have not been elucidated, we propose here that the DDX41 p.R525H mutation in hematopoietic stem/progenitor cells is involved in the pathogenesis of a certain subset of such AML cases.
Methods

Patient samples and cell fractionation
Bone marrow aspirates or peripheral blood specimens were collected from 23 patients with AML who participated in the study according to the protocol approved by the ethics committee on human genome research at Hiroshima University and Kumamoto University. The protocol was based on an opt-out or on written informed consent obtained by the patients. The protocol included the use of pooled samples at initial diagnosis. Total RNA was extracted from CD34-positive cell fractions isolated by magnetic activated cell sorting. Where possible, CD3-positive and CD34negative/CD3-negative fractions were isolated.
mRNA sequencing
In this study, gene mutations were screened upon mRNA sequencing. The libraries for mRNA sequencing were prepared according to the SureSelect library preparation kit (Agilent Technologies, Santa Clara, CA) and subjected to massively parallel sequencing with a GAIIX or Hiseq2500 sequencer (Illumina, San Diego, CA) using a single-end 36-bp or 50-bp sequencing length protocol. Sequenced tags were aligned to the human reference genome (build hg19) using ELAND (Illumina), and gene expression was normalized to the amount of reads per kilobase of exon per million mapped (rpkm).
Antibodies
The following antibodies were used in this study: anti-DDX41 (ab182007; Abcam, Cambridge, UK), anti-Actin (MAB1501; Merck Millipore, Darmstadt, Germany), anti-FLAG M2 (F3165; Sigma-Aldrich, St. Louis, MO), anti-Myc-tag (2272; Cell Signaling Technology, Danvers, MA), anti-Nucleolin (M019-3S; MBL, Nagoya, Japan), anti-RPL5 (ab86863; Abcam), anti-RPL11 (ab79352; Abcam), anti-RB (9313; Cell Signaling Technology), anti-phospho-RB (9301; Cell Signaling Technology), anti-MDM2 (ab3110; Abcam), and anti-multi-ubiquitin (D058-3; MBL).
Vector construction DDX41 and other cDNAs used in this study were obtained by polymerase chain reaction (PCR) amplification from human cord blood-derived total RNA and cloned into pMYs-IG retrovirus vector [3] . Point mutations and truncations were generated using a site-directed mutagenesis approach.
Cell culture and plasmid transfection Cord blood-derived CD34-positive cells were purchased from the RIKEN Cell Bank (Ibaraki, Japan). The cells were cultured on Tst4/min feeder cells (kindly provided by Dr. H. Kawamoto at Kyoto University) in Dulbecco's modified Eagle medium supplemented with 20% fetal bovine serum (FBS) in the presence of human stem cell factor (SCF), FMS-related tyrosine kinase 3 ligand (FLT3-L), and thrombopoietin (TPO; 100 ng/mL each). THP-1 and K562 cells were cultured in RPMI1640 medium containing 10% FBS. For enforced gene expression, pMYs-IG retroviral vector and PLAT-E or PLAT-F packaging cells were used.
Immunofluorescence analysis
Murine lung fibroblasts grown on coverslips were infected with a retrovirus and cultured for 2 days. THP-1 cells were first transduced with retrovirus and then attached to a glass slide using a cytospin apparatus. The cells were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100, and blocked with 1% bovine serum albumin (BSA), followed by staining with primary antibodies. After staining with Cy3-or Alexa Fluor 488-labeled secondary antibodies and Hoechst 33342, fluorescent signals were observed, and the images were taken using a confocal laser scanning microscope (LSM 5; Carl Zeiss Microscopy, Jena, Germany).
Immunoblot and immunoprecipitation analysis
Cells (1 Â 10 6 ) were extracted with NP40 lysis buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, and 1.0% NP40) containing proteinase and phosphatase inhibitor cocktails (Complete and Phos-STOP; Roche Life Sciences, Indianapolis, IN). For immunoprecipitation analysis, protein G-coated magnet beads (20 mL in each experiment) were conjugated with an antibody (4 mg) and mixed with cell extracts overnight at 4 C. The beads were washed five times with NP40 lysis buffer and then resuspended with 50 mL of sample buffer (NP40 lysis buffer containing 1% sodium dodecyl sulfate, 0.5% b-mercaptoethanol, and 12.5% glycerol), followed by denaturation and elution by heating at 95 C for 2 minutes. The samples were loaded and electrophoresed on 8.5%, 12.5%, or 15% polyacrylamide gels according to the molecular weight of the protein of interest.
Northern blotting analysis
Northern blotting analysis was performed based on a non-RI protocol according to the manufacturer's instructions (DIG Northern Starter Kit; Roche Life Sciences). Briefly, 1.5 mg of total RNA was denatured and fractionated using a denaturing gel (2% formaldehyde/1.2% agarose), followed by transfer to a nylon membrane. The membranes were hybridized with digoxigenin-labeled RNA probes, and the signals were detected using alkaline-phosphatase-labeled antidigoxigenin antibody and a chemiluminescent substrate. RNA probes in this assay were prepared by PCR amplification of internal transcribed spacer 1 (ITS1) and ITS2 regions (for ITS1, forward primer: 5 0 -acggagcccggagggcgaggcccgc-3 0 , reverse primer: 5 0 -cgtctccctcccgagttctcggctc-3 0 ; and for ITS2, forward primer: 5 0 -ctaagcgcagacccggcggcgtccg-3 0 , reverse primer: 5 0 -acgggaactcggcccgagccggctc-3 0 ), followed by in vitro transcription using DIG-11-UTP for probe labeling. The ITS1 probe was used for the identification of 47S, 45S, 30S, and 21S pre-rRNA, whereas the ITS2 probe was used for 47S, 45S, 32S, and 12S detection ( Supplementary Figures E1A and E1B , online only, available at www.exphem.org). Schematic pre-rRNA-processing pathways are shown in Supplementary Figure E1B .
ATPase assay
The assay reaction (10 mL) contained the following components: 50 mM Tris-HCl, pH 7.4, 20 mM MgCl 2 , 50 mM KCl, 3.33 pM [a-32 P]ATP, and 0.2 mg of helicase domain of DDX41 purified by an in vitro translation system (Trans-direct insect cell; Shimadzu, Kyoto, Japan). BSA was used as a negative control. Samples were incubated for 15 or 30 minutes at 37 C, and the reaction was stopped by adding 1 mL of 0.5M EDTA, pH 8.0. The reaction mixture (1 mL) was then spotted on a cellulose PEI-F plate (Avantor Performance Materials, Center Valley, PA) and developed by ascending chromatography in 0.75 M LiCl/1 M formic acid solution for 1 hour. The plate was air dried and the ATP/ADP signals were detected by autoradiography.
Mouse bone marrow transplantation (BMT) C57BL/6 (Ly5.1) mice (Sankyo Labo Service Corporation, Tokyo, Japan) and C57BL/6 (Ly5.2) mice (Charles River Laboratories Japan, Kanagawa, Japan) were used for BMT experiments. A total of 100,000 cells (Ly5.1) transduced with a DDX41/GFP expression vector was transplanted into sublethally irradiated recipient mice (Ly5.2), and peripheral white blood cell (WBC) numbers and green fluorescent protein signals were measured 2-3 months later.
Results
Identification of the DDX41 p.R525H mutation in three AML patients
We screened for the DDX41 mutation of CD34-positive tumor cells based on mRNA sequencing and identified a *mutaƟons previously reported as recurrent. N.I.: not indicated. heterozygous DDX41 c.G1574A (p.R525H) mutation (chr5: 176,939,370 on build GRCh37/hg19) in three cases among 23 patients ( Fig. 1A) . Although we did not perform comprehensive sequencing of paired germline DNA, we confirmed the mutation as somatic by the direct genome sequencing of CD3-positive cells (Fig. 1B) . Intriguingly, these patients, in addition to a patient with the same mutation enlisted in the Cancer Genome Atlas [4] , exhibited AML with peripheral and bone marrow cytopenias and low blast counts ( Fig. 1A) , although the precise cellularity of the bone marrow was undetermined because a bone marrow biopsy was not performed. In addition, a recent study described a germline p.R525H mutation associated with bone marrow hypocellularity and low WBC count in a primary AML patient [2] . According to our transcriptome data on patients' CD34-positive cells, almost one half of the sequenced tags at c.G1574 were considered mutated in each patient (18 of 37, 19 of 32, and 23 of 47 reads were called ''A''). Therefore, almost all CD34-positive cells in these patients may harbor a heterozygous DDX41 p.R525H mutation, although deeper sequencing analysis is required to assess the precise variant allele frequencies. Conversely, CD34-negative cells carrying the mutation were fewer compared with CD34-positive cells, and CD3-positive cells carrying the mutation were almost absent, as estimated by direct genomic DNA sequencing (Fig. 1B) . These data suggest a somatic nature of the mutation in the patient and a block in the differentiation of CD34-positive DDX41 mutant cells into negative cells.
Nuclear localization of the DDX41 protein
We next clarified the localization of the DDX41 protein. In this experiment, FLAG-tagged STING, a protein that had been reported to interact with DDX41 at the endoplasmic reticulum [5, 6] , was coexpressed with Myc-tagged DDX41 in fibroblasts. Ectopically expressed DDX41 was mostly nuclear regardless of the p.R525H mutation and minimally colocalized with FLAG-STING in a steady state ( Fig. 2A ). In the THP-1 leukemia cell line, the endogenous DDX41 protein was also mostly nuclear (Fig. 2B ). In the nucleus, DDX41 protein localized both in the nucleoplasm and in the nucleolus (stained with nucleolin), suggesting that DDX41 plays a role in the nucleoplasm as well as in the nucleolus. Although previous studies described DDX41 as a cytosolic DNA sensor that recognizes nucleic acids of pathogens [6] , our study did not suggest this function based on the protein localization. However, we identified a 52-kDa DDX41 short isoform translated from the second methionine in addition to the full-length 70-kDa DDX41 ( Fig. 2C; Supplementary Figures E2A and E2B , online only, available at www.exphem.org). This short form, which lacks a putative nuclear localizing signal (NLS) and is detected both in the cytoplasm and in the nucleus ( Fig. 2C; Supplementary Figure E2C , online only, available at www.exphem.org), might function as a sensor of pathogenic nucleic acids.
Growth inhibition of p.R525H DDX41-expressing cells due to impaired pre-rRNA processing To investigate the molecular functions of DDX41 in hematopoietic cells, cord blood-derived human CD34positive cells were transduced with wild-type (WT) or p.R525H DDX41 using a retroviral system [3] , followed by cultivation in the presence of 100 ng/mL SCF, TPO, and FLT3-L. After a 30-day culture, p.R525H cells showed decreased proliferation compared with WT cells (Fig. 3A) , and this was accompanied by the suppression of mRNAs encoding ribosomal proteins (Supplementary Figure E3A , online only, available at www.exphem.org). A gene set enrichment analysis (GSEA) [7] showed that the gene expression pattern of p.R525H cells was negatively correlated with ribosomal gene sets and with myc target genes (Supplementary Figure E3B , online only, available at www.exphem.org). GSEA further indicated an enrichment of the genes upregulated in the absence of RPS14 in p.R525H cells (Supplementary Figure E3B) . These data suggest that a certain ribosomopathy [8] may occur in the mutant DDX41-expressing cells. These findings and a highly conserved DEAD-box type RNA helicase domain of DDX41 led us to speculate that the DDX41 protein might be involved in pre-rRNA processing. A recent study also supports this speculation [9] . As expected from the position of the somatic mutation (p.R525), which is within the helicase core where the ATP binds and is hydrolyzed (Fig. 2C) [10] , the mutant helicase domain displayed a lower ATPase activity (Fig. 3B ). In addition, northern blot analysis probing ITS1 and ITS2 of pre-rRNA showed increased signals of 47S and 41S pre-rRNAs (Fig. 3C ). The 30S signal was slightly upregulated, whereas the 21S signal was decreased in THP-1 cells expressing p.R525H DDX41. Instead, the 32S signal was increased both in WT and p.R525H cells. Furthermore, semiquantitative real-time PCR experiments showed relatively higher amounts of pre-rRNA containing 5 0 external transcribed spacer (ETS) or ITS2 than that containing ITS1 in p.R525H cord blood cells (Fig. 3D) . Although the precise phase at which DDX41 takes part in pre-rRNA processing has not been elucidated, this series of experiments suggests a role for DDX41 in the trimming of 5 0 ETS and/or ITS2.
Activation of RB pathway occurring in p.R525H DDX41-expressing cells As mentioned previously, p.R525H DDX41 cord blood cells were fewer than WT cells after the culture (Fig. 3A) , but the induction of apoptosis was unlikely because cell viability was maintained at almost 100% throughout the culture (data not shown). Recent studies on ribosomopathies revealed an activation of the MDM2-p53 pathway in the pathogenesis of the diseases [11, 12] . It is now widely recognized that RPL5 and RPL11 not incorporated into the 60S ribosome bind preferentially to MDM2, so inhibition of p53 by MDM2 is compromised, causing a stimulation of the p53 pathway [13, 14] . We initially assumed that the same defect might be involved in the growth impairment of p.R525H DDX41 cells. Nevertheless, GSEA did not indicate p53 activation in the cells, probably because we cultured cord blood cells with a combination of cytokines (SCF, FLT3-L, and TPO). This combination is expected to expand hematopoietic stem/ progenitor cells with less differentiation. Data from transcriptome analysis suggested no erythroid differentiation in this culture condition, in which globin genes were almost not expressed at all. Given that ribosomal defect-mediated activation of p53 pathway occurs preferentially in the erythroid lineage in ribosomopathies, our culture conditions might not have been optimal to observe p53 activation. Instead, GSEA revealed a negative enrichment of cell cycle-promoting genes regulated by the RB-E2F axis in p.R525H DDX41 cord blood cells (Fig. 4A) . Cell cycle inhibition through the suppression of E2F activity was also detected in patient-derived samples (Fig. 4B) . In our study, (Supplementary Figure E1A) . The right panels indicate lane profile plots generated from the northern blots (left panels) using ImageJ software and quantitative values of each pre-rRNA band relative to the empty vector control. (D) Relative amounts of pre-rRNA spacers as assessed by quantitative PCR analysis. Empty vector or DDX41 (p.R525H and WT)-transfected cord blood cells were subjected to quantitative PCR experiments. The regions amplified by PCR are shown in Supplementary Figure E1A. we found increased RPL5 and RPL11 bound to MDM2 in p.R525H DDX41 cells (Fig. 4C ). Because the total amount of these ribosomal proteins was apparently not altered by the enforced expression of p.R525H DDX41, the mutant DDX41 might increase free ribosomal proteins that are not incorporated into the 60S ribosome, and these proteins may eventually form a complex with MDM2. Moreover, the RB protein was increased in p.R525H DDX41 cells, in part due to the inhibition of MDM2-mediated polyubiquitination (Fig. 4D ). The RB protein was active in p.R525H DDX41 cells because it was dephosphorylated, although the mechanism of the dephosphorylation is currently unclear. Furthermore, impaired growth was observed in p.R525H DDX41 THP-1 cells lacking WT p53 (Supplementary Figure E4A , online only, available at www.exphem.org) [15] , implying a p53-independent but RB-dependent cell cycle inhibition by the mutant DDX41.
Discussion
In this study, we performed mRNA sequencing on 23 patients and identified the DDX41 p.R525H mutation in three AML patients. The rate of somatic DDX41 mutation was high compared with previous studies because of our limited number of patients or because of the use of CD34-positive cells in our study. In most previous studies, whole genome or exome sequencing was performed using total bone marrow or peripheral blood specimens. Given that tumor cells harboring the DDX41 mutation rarely divide and differentiate, a screening using whole hematopoietic cells might fail to detect mutations of such a rare population, thus underestimating the rate of DDX41 mutation among AML/MDS patients.
DDX41 protein is a DEAD-box type ATP-dependent RNA helicase [10] in which the helicase domain is highly conserved. DEAD-box RNA helicases have been shown to act in many pathways, including pre-mRNA splicing and ribosome biogenesis. In addition, recent studies propose roles of RNA helicases, such as RIG-I, in sensing nucleic acids of microbes incorporated into cells [16, 17] . In addition, some DEAD-box RNA helicases have multiple functions and have been involved in tumorigenesis [18, 19] . However, the function of DDX41 has not been investigated until recently. A recent study reported that DDX41 cooperates with mRNA-splicing factors and is involved in late spliceosomal processing [1] . However, as we mentioned previously, we identified a DDX41 p.R525H mutation in AML patients exhibiting cytopenias in bone marrow and peripheral blood, the pathogenesis of which has not been known to be connected to mRNA splicing defect. Therefore, we further investigated the biological functions of DDX41 and its contribution to the development of AML through an acquired mutation. The DDX41 localizes at the nuclear matrix and in the nucleolus, consistent with the putative NLS at the N-terminus. However, contrary to our observation, a recent study described DDX41 localization in the cytoplasm even when a full-length cDNA was transfected [6] . The reason for the discrepancy between our observation and observations from others is not obvious, but it might be possible that a short form that we identified for the first time in this study was mainly expressed in previous studies describing DDX41 in the cytoplasm. Because it has also been reported that human DDX41 shuttles between the nucleus and cytoplasm [20] , it could be also possible that cells in which DDX41 is localized mainly in the cytoplasm were used in previous studies.
Although the enforced expression of WT DDX41 in cord blood-derived cells had minimal effects, substitution of p.R525 into histidine induced cell cycle arrest, suggesting that this alteration interferes with cell growth in a dominant-negative manner. In addition, as expected, the inhibitory effect of p.R525H DDX41 on cell cycle progression is due to the loss of ATPase activity. Unexpectedly, the cell cycle arrest was MDM2-and RB-dependent, but p53independent. However, this is consistent with previous studies arguing that MDM2-dependent but p53independent pathways also cause ribosomopathies [21, 22] .
Our results further indicate an interference of p.R525H DDX41 in pre-rRNA processing, giving rise to a certain ''ribosomal stress.'' In humans, the 18S, 5.8S, and 28S rRNA molecules are transcribed by RNA polymerase I as a single precursor called 47S pre-rRNA [23] , which is then modified and cleaved post-transcriptionally into mature rRNA (Supplementary Figure E1B) [24] . The processing of pre-rRNA occurs mainly in the nucleolus, where w4,500 putative nucleolar proteins and small nucleolar RNAs are thought to participate in this process [25] . Although the molecular functions of almost none of the nucleolar proteins have been elucidated (with some exceptions), a recent study that performed siRNA-mediated depletion of 625 candidate nucleolar proteins helped to explain the pre-rRNA processing machinery [9] . Because it has been shown that some spliceosomal factors, such as hPrp43/DHX15 RNA helicase, also participate in pre-rRNA processing [26, 27] , DDX41 could play multiple roles. We think that this pathway can at least partly account for the development of AML with cytopenias harboring the DDX41 p.R525H mutation. Hematopoietic stem cells have a low level of protein synthesis compared with differentiating or growing progenitor cells [28] . Assuming that AML stem cells with the DDX41 p.R525H mutation are constitutively in a lowprotein synthesis status due to ribosomal stress, the cells could be able to be maintained under this stress, but they cannot proliferate or differentiate, which would explain in part the pathophysiology of a slowly growing AML. In summary, we propose a mechanism of growth defect in hematopoietic cells triggered by p.R525H DDX41 occurring in the following order: (1) the p.R525H mutant inhibits pre-rRNA processing; (2) compromised ribosomal biogenesis as a result of impaired rRNA synthesis causes a release of ribosomal proteins that bind to MDM2; and (3) MDM2mediated RB degradation is suppressed, eventually activating the RB pathway and resulting in the inhibition of E2F activity. Although this study uncovered a pathogenic role of p.R525H DDX41 in the slow growth rate of tumor cells, how the mutation induces AML development and inhibits cell differentiation is still not understood. Lethally irradiated mice transplanted with hematopoietic stem/progenitor cells overexpressing p.R525H DDX41 did not develop myeloid malignancy, even in the p53-deficient background (Supplementary Figure E4B , online only, available at www.exphem.org). Considering the late occurrence of AML in patients harboring the mutation, age-dependent epigenetic alterations or other somatic changes may be required for this mutation to transform hematopoietic cells fully. Figure E1 . Structure and processing pathways of pre-rRNA. (A) Structure of 47S pre-rRNA. The 5 0 and 3 0 ETS and ITS 1 and 2 are spacer regions that will be removed during pre-rRNA processing, and there are many pre-rRNA intermediates partially retaining these spacers, as shown in (B). Detailed pre-rRNA cleavage sites and their names are described in a recent review [24] . The regions used for northern probes (ITS1 and ITS2) and amplified by quantitative PCR analysis (5 0 -01, 01-A0, A0-1, 3-E, E-C, 2-5.8S, and 4 0 -4a) are shown in orange and gray, respectively. (B) Schematic processing pathways of pre-rRNA. Three rRNAs (18S, 5.8S, and 28S) are first transcribed as a long polycistronic precursor designated as 47S pre-rRNA. The latter will subsequently be processed to produce mature rRNAs through pathways, as shown in this schema. 754.e1 M. Kadono et al./ Experimental Hematology 2016; 44:745-754 
